GT Biopharma Advances Three TriKE Programs after Cohort 4 Success at $13M Market Cap
IBRX•GT Biopharma carries a $13 million market cap while advancing three Tri-specific Killer Engager candidates in human trials, including GTB-3650 in Phase 1 for AML/MDS with four cohorts completed and no dose-limiting toxicities. The company dosed its first GTB-5550 patient in May, targeting B7-H3-expressing solid tumors with subcutaneous delivery.
1. Market Cap and Pipeline Overview
GT Biopharma operates with a market capitalization of roughly $13 million and holds an exclusive license from the University of Minnesota for its Tri-specific Killer Engager (TriKE) platform. The company has progressed three distinct TriKE candidates into human trials, positioning it as a clinical-stage immuno-oncology player focused on natural killer cell engagement.
2. GTB-3650 Phase 1 Progress
The lead candidate, GTB-3650, targets relapsed or refractory CD33-positive blood cancers including AML and high-risk MDS. As of the Q1 2026 report, Cohort 4 enrollment is complete with eight patients treated and no dose-limiting toxicities observed; the trial can escalate through seven cohorts with a meaningful data update expected in the second half of 2026.
3. GTB-5550 Solid Tumor Program
In May 2026, GT Biopharma dosed the first patient in the Phase 1 trial of GTB-5550, a TriKE targeting the B7-H3 protein found in over 90% of metastatic prostate cancers and expressed across multiple solid tumors. The study begins with prostate cancer dose escalation and will expand into a basket trial covering up to seven tumor types, using subcutaneous injections to enhance patient convenience.
4. Large Oncology Market Opportunity
The global oncology market is projected to grow from approximately $139 billion in 2025 to about $268 billion by 2034, with solid tumors representing a significant portion of that expansion. NK-cell-directed immunotherapy is gaining attention for its potential to harness the body’s innate defenses with fewer side effects, creating a sizable market opportunity for TriKE-based therapies.
